Arbutus Biopharma Updates Corporate Presentation, Reports $104.6M in Cash
Arbutus Biopharma updated its corporate presentation, reporting $104.6M in cash as of October 31, 2026. The company highlighted its hepatitis B pipeline, including 46% of Phase 2a patients achieving functional cure or discontinuing therapy, and plans for a potential Phase 2b imdusiran trial. AB-101 Phase 1 findings showed full PD-L1 receptor occupancy in 11 of 13 healthy subjects at 40 mg.
How this was made
The 30-second read
Why it matters
The disclosed functional‑cure rate and cash runway provide new material information that could shift valuation.
Market read
First disclosure of trial outcomes and cash position; likely to influence ABUS price action.
What to watch
Cash balance, while sizable, may be insufficient for later‑stage trials without additional financing.
Background
Arbutus Biopharma filed an 8‑K presenting updated cash position and early clinical data for its hepatitis B candidate imdusiran.
Ticker impact
Corporate presentation disclosed $104.6M cash and Phase 2a functional‑cure data (46% of patients) for imdusiran.
likely upside as market prices in the functional‑cure data.
Trial data is material for a biotech; cash runway supports further development.
Market effects
May boost sentiment for hepatitis B therapeutics and related biotech peers.
Limited to US biotech sector.
Modest; primarily affects investors tracking early‑stage liver disease pipelines.
Counterpoint
Data may not translate to Phase 2b success; investors should watch for longer‑term efficacy.
Key entities
- companyArbutus Biopharma
Biotech developing hepatitis B therapies.